Richard Estick

QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions

Retrieved on: 
Tuesday, October 19, 2021
Biotechnology, Medical Supplies, Health, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Other Health, Calibration, Molecular diagnostics, Union, Life, Richard Estick, List of life sciences, Technology, Commission on Sustainable Development, COVID-19, Budget, Lung, Diagnosis, QGEN, Stop TB Partnership, NYSE, Growth, Transport, Tuberculosis, RNA, Annual report, Disease, Lists of disasters, Weather, Knowledge, U.S. Securities and Exchange Commission, Infection, CEO, QIAGEN, Patient, CE, QuantiFERON, Automation, Clinical, Conference, TB, Protein, Partnership, Interferon gamma release assay, ZAMBART Project, Blood, Solution, IGRA, DNA, Marketing, Maintenance, Data management, Heating, ventilation, and air conditioning, Medical imaging, Pharmaceutical industry

QIAGEN will focus on regions that face a high burden of the disease, and where getting access to lab infrastructure and resources for testing are limited.

Key Points: 
  • QIAGEN will focus on regions that face a high burden of the disease, and where getting access to lab infrastructure and resources for testing are limited.
  • With QIAreach QuantiFERON-TB we have taken a great step towards leaving no one behind when facing a deadly disease like tuberculosis that is preventable and curable.
  • A quantum leap from the traditional TB skin test, QuantiFERON-TB uses blood samples to test for interferon-gamma molecules released from T-cells that have come into contact with TB bacteria.
  • QIAreach QuantiFERON-TB runs these tests on the digital eHub and eStick system, a true walkaway solution with random access and no calibration or maintenance.

QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen

Retrieved on: 
Friday, August 6, 2021
Biotechnology, FDA, Health, Pharmaceutical, Managed Care, Growth, Budget, List of life sciences, U.S. Securities and Exchange Commission, Food, EUA, Molecular diagnostics, Solution, QGEN, COVID-19, Technology, Infection, Deep Ellum, Dallas, Patient, Life, Partnership, Knowledge, Blood, FDA, Severe acute respiratory syndrome coronavirus 2, SEC, NYSE, Richard Estick, Time, RNA, Research, Protein, Automation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19 testing, DNA, Vaccine

The rapid portable test can detect SARS-CoV-2 antigen in people with active infections in 2 to 15 minutes and can process an average of around 30 swab samples per hour, providing digital test results that do not require subjective interpretation.

Key Points: 
  • The rapid portable test can detect SARS-CoV-2 antigen in people with active infections in 2 to 15 minutes and can process an average of around 30 swab samples per hour, providing digital test results that do not require subjective interpretation.
  • The QIAreach SARS-CoV-2 Antigen Test is the second QIAGEN COVID-19 test to make use of the digital eHub and eStick system that was developed in partnership with Australian digital diagnostics company Ellume.
  • In May 2021, QIAGEN received an EUA for its QIAreach Anti-SARS-CoV-2 Total Test that uses the same technology and eHub.
  • The test has the capacity to analyze nasal and nasopharyngeal swab samples from up to eight symptomatic patients simultaneously.